⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
AUROPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.7
| Stock Code | AUROPHARMA | Market Cap | 68,250 Cr. | Current Price | 1,175 ₹ | High / Low | 1,279 ₹ |
| Stock P/E | 33.8 | Book Value | 369 ₹ | Dividend Yield | 0.34 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,175 ₹ | DMA 200 | 1,162 ₹ |
| Chg in FII Hold | -0.26 % | Chg in DII Hold | 0.06 % | PAT Qtr | 581 Cr. | PAT Prev Qtr | 559 Cr. |
| RSI | 49.7 | MACD | -9.15 | Volume | 7,70,528 | Avg Vol 1Wk | 23,18,641 |
| Low price | 994 ₹ | High price | 1,279 ₹ | PEG Ratio | 7.91 | Debt to equity | 0.21 |
| 52w Index | 63.6 % | Qtr Profit Var | 8.16 % | EPS | 34.8 ₹ | Industry PE | 29.1 |
📈 Technical Analysis
- Chart Patterns: Price is aligned with 50 DMA (1,175 ₹) and slightly above 200 DMA (1,162 ₹), showing consolidation.
- Moving Averages: Current price (1,175 ₹) is at 50 DMA and above 200 DMA, suggesting neutral to mildly bullish bias.
- RSI: Neutral at 49.7, neither overbought nor oversold.
- MACD: Negative (-9.15), indicating short-term bearish momentum.
- Bollinger Bands: Price is mid-range, showing consolidation without breakout signals.
- Volume Trends: Current volume (7,70,528) is well below 1-week average (23,18,641), indicating reduced participation.
📊 Momentum & Trend
- Short-term Momentum: Weak, with MACD negative and RSI neutral.
- Support Zone: 1,160 ₹ – 1,170 ₹ (near 200 DMA).
- Resistance Zone: 1,190 ₹ – 1,200 ₹ (recent highs).
- Trend: Consolidating with mild bearish bias.
- Optimal Entry: Around 1,160 ₹ – 1,170 ₹ if support holds.
- Optimal Exit: Around 1,190 ₹ – 1,200 ₹ unless breakout occurs.
✅ Positive
- Consistent PAT growth (581 Cr vs 559 Cr previous quarter).
- EPS of 34.8 ₹, showing profitability.
- Dividend yield of 0.34% provides some investor returns.
⚠️ Limitation
- ROCE (10.8%) and ROE (8.65%) are modest compared to peers.
- High P/E (33.8) vs industry average (29.1), suggesting overvaluation.
- PEG ratio of 7.91 indicates expensive valuation relative to growth.
📉 Company Negative News
- FII holding decreased (-0.26%), showing reduced foreign investor confidence.
📈 Company Positive News
- DII holding increased (+0.06%), showing domestic institutional support.
- Quarterly profit growth of 8.16% indicates operational improvement.
🏭 Industry
- Industry PE at 29.1, lower than company PE, suggesting valuation premium.
- Sector remains steady with moderate growth outlook.
🔎 Conclusion
- Stock is consolidating with mild bearish signals.
- Entry near support (1,160 ₹ – 1,170 ₹) could be favorable for short-term traders.
- Exit near resistance (1,190 ₹ – 1,200 ₹) unless breakout confirms trend continuation.
- Long-term investors should be cautious due to stretched valuations despite steady earnings growth.